There are inadequate numbers of cancer clinical investigators to translate basic science advances into patient benefit. One reason for this shortage is inadequate clinical investigator training. Johns Hopkins is poised to address this deficiency. In July, 1992 it will inaugurate a training program for clinical investigators. The Oncology Center was a leader in the development of this program. As a comprehensive cancer center there are abundant opportunities for clinical research at Johns Hopkins in established research programs at the lab-clinic interface. These programs have a record of training successful clinical investigators. This application describes a Clinical Oncology Research Career Development Program (CORCDP) that will train-oncologists to translate basic science advances into improved cancer prevention, detection, diagnosis and treatment. The CORCDP will be under the direction of Martin D. Abeloff, M.D., Director, Stephen B. Baylin, M.D. and John H. Fetting, M.D., Co-Directors, and a representative Advisory Committee. Faculty will be established investigators in research programs at the lab-clinic interface. The core of the three year CORCDP will be the Johns Hopkins, program to train clinical investigators which combines courses on clinical investigation with mentored clinical research and results in a Master's Degree. Trainees in the CORCDP will have electives involving both cancer basic science and clinical trials and will perform clinical research at the lab-clinic interface. The CORCDP will enable the Oncology Center to be a major participant in the Johns Hopkins' program. Trainee candidates from medical, pediatric, radiation, and surgical oncology fellowships or residencies will be selected on a rotating basis to assure that the CORCDP is available to all subspecialties. Two or three fellows will be selected yearly. When fully operational, seven or eight fellows will be in the CORCDP at a time. Special efforts will be made to recruit minority candidates. Regular evaluation of the CORCDP is planned. The CORCDP will be successful if it trains productive clinical investigators.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (72))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Mathieu, L N; Kanarek, N F; Tsai, H-L et al. (2014) Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). Dis Esophagus 27:757-63
Brewster, A M; Jorgensen, T J; Ruczinski, I et al. (2006) Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer. Breast Cancer Res Treat 95:73-80
Strouse, John J; Cox, Christiane S; Melhem, Elias R et al. (2006) Inverse correlation between cerebral blood flow measured by continuous arterial spin-labeling (CASL) MRI and neurocognitive function in children with sickle cell anemia (SCA). Blood 108:379-81
Strouse, John J; Fears, Thomas R; Tucker, Margaret A et al. (2005) Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 23:4735-41
Brewster, Abenaa M; Alberg, Anthony J; Strickland, Paul T et al. (2004) XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 13:1271-5
Jacobsohn, David A; Vogelsang, Georgia B (2002) Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 62:879-89
Friedmann, Alison M; Sengul, Haydar; Lehmann, Harold et al. (2002) Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 16:34-45
Gillison, M L; Koch, W M; Capone, R B et al. (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-20
Dees, E C; O'Reilly, S; Goodman, S N et al. (2000) A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 18:521-9
Carey, L A; Kim, N W; Goodman, S et al. (1999) Telomerase activity and prognosis in primary breast cancers. J Clin Oncol 17:3075-81

Showing the most recent 10 out of 16 publications